Autolus Therapeutics is gearing up to announce its quarterly earnings on March 14, 2024. Analysts are expecting an EPS of $-0.25 for the company. Investors are eagerly awaiting the results to see if Autolus Therapeutics will exceed this forecast and provide a positive outlook for the next quarter.
In the previous quarter, Autolus Therapeutics fell short of EPS expectations by $0.01, but the share price saw a significant increase of 20.65% the following day. Here is a recap of Autolus Therapeutics’ recent EPS estimates and actual results:
– Q3 2023: Estimate $-0.25, Actual $-0.26, Price Change 21.0%
– Q2 2023: Estimate $-0.22, Actual $-0.26, Price Change 1.0%
– Q1 2023: Estimate $-0.27, Actual $-0.23, Price Change -2.0%
– Q4 2022: Estimate $-0.27, Actual $-0.23, Price Change 6.0%
On March 12, Autolus Therapeutics’ shares were trading at $5.39, showing a positive return of 150.47% over the past year. Long-term shareholders are likely feeling optimistic about the upcoming earnings announcement.
For more in-depth forecasts and analyst ratings on Autolus Therapeutics, you can consult platforms like Tipranks, MarketBeat, Nasdaq, and Yahoo Finance.
Autolus Therapeutics plc (AUTL) Stock Price Sees Slight Decline on March 13, 2024: Market Analysis and Investment Considerations
On March 13, 2024, Autolus Therapeutics plc (AUTL) saw a slight decrease in its stock price, with shares dropping by $0.05 or 0.93% since the previous market close. The stock opened at $5.33, which was $0.06 lower than its previous closing price. AUTL is currently trading in the middle of its 52-week range and above its 200-day simple moving average, indicating relative stability over the past year. Daily stock price movements can be influenced by various factors, including market conditions, company news, and investor sentiment. Investors should conduct thorough research, consider their risk tolerance, and consult with a financial advisor before making investment decisions. Overall, AUTL’s performance on March 13, 2024, reflects a minor decline in the stock price, but the company remains relatively stable compared to historical averages. Monitoring market conditions and company news is important for making informed investment decisions.
Autolus Therapeutics PLC (AUTL) Stock Performance and Financial Data Analysis – March 13, 2024
On March 13, 2024, investors and analysts were closely monitoring the stock performance of Autolus Therapeutics PLC (AUTL) as the company’s financial data painted a mixed picture of its recent performance. According to data from CNN Money, AUTL’s total revenue was currently unavailable, making it difficult to gauge the company’s overall financial health. However, the net income figures provided some insight into the company’s profitability.
In the past year, AUTL reported a net income of -$148.84 million, which represented a 4.75% decrease compared to the previous year. In the most recent quarter, the company’s net income improved slightly to -$45.85 million, showing a 0.65% increase from the previous quarter. While the net income figures were in the negative, the quarter-over-quarter improvement could be seen as a positive sign for the company.
Earnings per share (EPS) also showed a similar trend, with a year-over-year increase of 20.52% to -$1.57 and a quarter-over-quarter increase of 0.57% to -$0.26. The improvement in EPS indicated that the company’s earnings were on the rise, albeit still in the negative territory.
Overall, AUTL’s stock performance on March 13, 2024, was likely influenced by the mixed financial data provided by the company. While the net income and EPS figures showed some improvement in the most recent quarter, the overall negative numbers could have dampened investor sentiment. As always, investors should conduct thorough research and analysis before making any investment decisions, especially when dealing with companies with fluctuating financial performance like AUTL.
